Development Pipeline (as of May 2025)

We are building a strategic portfolio that balances short-term revenue generation with long-term growth.

*Please click here to see why we target each disease.

① Application 1 for EXP01: Treatment for Lung Disorders (IPF, ARDS)

EXP01 is an EV (Extracellular Vesicle) formulation derived from bone marrow-derived mesenchymal stem cells (MSCs). Utilizing our proprietary cell activation technology, it features potent anti-inflammatory and anti-fibrotic effects with a low risk of side effects. It is expected to have applications in various disease areas, primarily inflammatory and fibrotic diseases. We are conducting R&D to first develop EXP01 as a therapeutic agent for lung disorders, specifically idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). We have completed a data package from non-clinical pharmacology, pharmacokinetics, and safety studies, and are preparing to conduct clinical trials in the United States.
Furthermore, in 2024, with a view to future domestic clinical trials and expansion to other respiratory diseases, we began a joint research project with Professor Hidenori Kage and his team at the University of Tokyo's Graduate School of Medicine.

② Application 2 for EXP01: Treatment for Atopic Dermatitis (AD)

The treatment of atopic dermatitis (AD) has advanced significantly with the advent of biologics and JAK inhibitors. However, significant unmet medical needs remain, including cases of steroid resistance in inducing remission and the difficulty of maintaining long-term remission.
Our "EXP01" presents a new therapeutic concept for these challenges: "suppressing the recurrence of inflammation and restoring the skin's original healthy state" through topical administration. EXP01's excellent anti-inflammatory and tissue-repairing capabilities are expected to induce remission even in refractory lesions effectively.
Furthermore, its effects are not limited to transient symptom suppression. Promoting the reconstruction of the skin barrier function and normalizing the immune environment can become a fundamental therapy that enables sustained post-treatment effects—in other words, long-term remission.
We seek partners to advance this unique therapeutic concept's clinical development jointly.

③ Application 3 for EXP01: Treatment for Chronic Kidney Disease (CKD)

CKD is characterized by tissue changes, primarily epithelial cell damage and fibrosis. Since EXP01 demonstrates effects in suppressing epithelial cell death and inhibiting fibroblast-mediated fibrosis, CKD is considered a promising target disease. Therefore, in 2024, we initiated joint research with Assistant Professor Yutaro Mori of the Graduate School of Medical and Dental Sciences at Tokyo University of Science. Dr. Mori develops an evaluation system with high clinical predictability for drug efficacy, using kidney tubular organoids derived from CKD patients. We will conduct efficient and highly clinically predictive efficacy evaluations using these CKD patient-derived organoids.

④ Application for EXP02: Reproductive Medicine, Infertility Treatment (Additive for In Vitro Fertilization - IVF)

EXP02 is an EV formulation derived from umbilical cord MSCs. Through our proprietary manufacturing process, it is rich in molecules crucial for the development of oocytes and sperm. Experiments in mice have confirmed that adding a small amount to the in vitro fertilization culture medium significantly improves poor embryonic development. We aim to market it to fertility clinics as an additive to increase the success rate of IVF.
For this development, we receive umbilical cord MSCs from Associate Professor Tokiko Nagamura of The Institute of Medical Science Hospital, The University of Tokyo, and research advice from Associate Professor Keiichi Kumasawa of the University of Tokyo's Graduate School of Medicine. Starting in fiscal year 2025, we began joint research with Assistant Professor Hiroki Takechi of the Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, to evaluate its effect on maturing immature oocytes.
The NEDO (New Energy and Industrial Technology Development Organization) DUSU program has supported this development since fiscal year 2024.

⑤ Application for EXP03 Flu: Seasonal Influenza Vaccine

EXP03 Flu is a nasally administered vaccine for preventing respiratory infectious diseases, utilizing engineered EVs. By efficiently displaying viral surface antigens on the EV membrane, it is expected to induce both mucosal and systemic immunity, providing a preventive effect against airborne infectious diseases like influenza and COVID-19.

⑥ Application for EXP03 AI: Treatment for Autoimmune Diseases

EXP03 AI is a therapeutic agent for autoimmune diseases that uses engineered EVs to induce antigen-specific immune tolerance. It aims to treat autoimmune diseases fundamentally by loading disease-associated antigens onto the EV membrane to suppress excessive immune responses selectively.